Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
Yi-Long Lung Cancer Wu, Caicun Zhou, Chengping Hu et al. · The Lancet Oncology · 2014
Cited by 1,975 works. doi:10.1016/s1470-2045(13)70604-1
Authors
- Yi-Long Lung Cancer Wu
- Caicun Zhou
- Chengping Hu
- Jifeng Feng
- Shun Lü
- Yunchao Huang
- Wěi Li
- Mei Hou
- Jian Hua Shi
- Kye Young Lee
- Chong‐Rui Xu
- Dan Massey G
- Miyoung Kim
- Yang Shi
- Sarayut Lucien Geater
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- AJCC Cancer Staging Manual
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
- COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
- Interpreting the significance of changes in health-related quality-of-life scores.
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial